Cullinan Therapeutics, Inc.
NASDAQ:CGEMMedical - Pharmaceuticals
+$0.62 today
- Market cap
- $584.94M
- Beta
- 0.01
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$3.73
Volume 1.06M
Average 0.99M
Returns on capital
Cullinan Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-53.8%
avg -2.3%
ROIC
-58.7%
avg -27.9%
ROA
-49.0%
avg -23.5%
Analysis
ROA is currently the strongest return metric at -49.0% versus its period average of -23.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Nadim Ahmed | President, Chief Executive Officer & Director | USD 1.17M | 58 | 390.80K | 0.64% |
Jeffrey Jones | Chief Medical Officer | USD 801.78K | 55 | — | — |
Mary Kay Fenton | Chief Financial Officer | USD 768.26K | 62 | 127.92K | 0.21% |
Patrick A. Baeuerle | Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board | USD 763.73K | 68 | — | — |
Corinne Savill | Chief Business Officer | — | 67 | — | — |
Jennifer Michaelson | Chief Scientific Officer | — | 59 | 75.18K | 0.12% |
Steve Andre | Chief Human Resources Officer | — | — | — | — |
Jacquelyn L. Sumer | Chief Legal Officer, Chief Compliance Officer & Corporate Secretary | — | 48 | 130.56K | 0.21% |
Rose Weldon | Senior Vice President of Corporate Affairs | — | — | — | — |
Nicholas Smith | Head of Investor Relations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 5, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
29
$2.56M
Net Transaction Value
−$2.56M
Net selling
Most Active
Michaelson Jennifer
19 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 5, 26Nov 5, 2026 | Michaelson Jennifer Direct | Sell | $49.4K$49,440.00 |
| Sep 8, 26Sep 8, 2026 | Michaelson Jennifer Direct | Sell | $172.6K$172,560.00 |
| Aug 13, 26Aug 13, 2026 | Michaelson Jennifer Direct | Sell | $607.8K$607,800.00 |
| Jul 6, 26Jul 6, 2026 | Michaelson Jennifer Direct | Sell | $142.6K$142,560.00 |
| May 5, 26May 5, 2026 | Michaelson Jennifer Direct | Sell | $113.9K$113,880.00 |
| May 5, 26May 5, 2026 | Michaelson Jennifer Direct | Sell | $3.1K$3,116.00 |
| Mar 5, 26Mar 5, 2026 | Michaelson Jennifer Direct | Sell | $125.4K$125,440.00 |
| Feb 25, 26Feb 25, 2026 | Michaelson Jennifer Direct | Sell | $25.2K$25,169.20 |
| Feb 24, 26Feb 24, 2026 | AHMED NADIM Direct | Sell | $195.6K$195,562.05 |
| Feb 24, 26Feb 24, 2026 | Michaelson Jennifer Direct | Sell | $52.1K$52,106.47 |
1–10 of 29
Summary
Insiders reported 0 buys worth $0.00 and 29 sells worth $2.56M over the last 12 months. That adds up to net selling of $2.56M. Michaelson Jennifer was the most active insider with 19 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Cullinan Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about CGEM's management, answered from reported figures.
Who manages CGEM?
Cullinan Therapeutics, Inc. (CGEM) lists 10 active executives. The top listed executive is Corinne Savill, Chief Business Officer.
Are CGEM insiders buying or selling?
Recent insider activity shows net buying of $64.05M.
Continue the stock analysis
Jump to another research area for this company.